Valvular & structural heart disease
The Impact of Frailty on VARC-3 Integrated Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement
Authors' conclusion
More than 1 in 6 patients with severe aortic stenosis undergoing TAVR were considered frail in the SCOPE I trial. Patients with frailty had a similar improvement in patient-reported health status measures after TAVR, but a higher risk of unfavorable outcomes throughout 3 years of follow-up.
Study context
- Population
- Patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) in the SCOPE I trial, stratified according to frailty
- Participants
- 739 randomized patients
- Comparison
- Patients with vs without frailty undergoing TAVR
- Frailtyn = 122
Methodological detailsrandomized
- Randomized
Primary result
As reported in the abstract
Baseline characteristics (mean age, comorbidities, surgical risk)
- Mean age, comorbidities, and surgical risk were comparable between groups
Further findings
| Outcome | Risk ratio (95% CI) | |
|---|---|---|
| VARC-3 clinical efficacy · 3 years after TAVRTowards reduced VARC-3 clinical efficacy with frailty | 0.82 (0.65–1.03) | |
| 0.512Risk ratio (log scale) |
| Outcome | Risk ratio |
|---|---|
| VARC-3 unfavorable outcome · 3 years after TAVR | 1.38 |
- VARC-3 unfavorable outcome: increased risk with frailty; the CI is not printed legibly in the abstract
Patient-reported health status measures · after TAVR
- Patients with and without frailty had similar improvement in patient-reported health status measures after TAVR
Prevalence of frailty
- Patients who met the definition of frailty
- 122 patients (16.5%)
Original publication
The Impact of Frailty on VARC-3 Integrated Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC Adv. Published 14 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →